Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

2 terminated/withdrawn out of 18 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 2
11(64.7%)
Phase 1
5(29.4%)
N/A
1(5.9%)
17Total
Phase 2(11)
Phase 1(5)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT06443463Phase 2Enrolling By Invitation

Long-term Safety and Tolerability of BHV-7000

Role: lead

NCT06132893Phase 2Recruiting

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Role: lead

NCT06309966Phase 2Recruiting

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Role: lead

NCT07262268Phase 1Enrolling By Invitation

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Role: lead

NCT06423781Phase 2Completed

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT06425159Phase 2Terminated

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

Role: lead

NCT07281495Phase 2Active Not Recruiting

Taldefgrobep Alfa in Adults With Overweight and Obesity

Role: lead

NCT06980649Phase 1Recruiting

Study of BHV-1300 in Graves' Disease

Role: lead

NCT06384807Phase 1Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Role: lead

NCT07054684Phase 1Recruiting

Study of BHV-1400 in IgA Nephropathy

Role: lead

NCT06603623Phase 2Completed

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Role: lead

NCT06976268Phase 2Recruiting

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Role: lead

NCT06529146Active Not Recruiting

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Role: lead

NCT06419608Phase 2Completed

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Role: lead

NCT06419582Phase 2Completed

BHV-7000 Acute Treatment of Bipolar Mania

Role: lead

NCT06423794Phase 2Terminated

BHV-7000 Open-Label Extension Bipolar Mania Study

Role: lead

NCT06874335Phase 1Recruiting

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Role: lead

NCT06419322Not ApplicableActive Not Recruiting

Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).

Role: collaborator

All 18 trials loaded